Acadian Asset Management LLC Makes New $26,000 Investment in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Acadian Asset Management LLC purchased a new position in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 6,598 shares of the company’s stock, valued at approximately $26,000.

Separately, Vanguard Group Inc. raised its stake in shares of Vigil Neuroscience by 11.9% during the 1st quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock worth $3,050,000 after buying an additional 95,276 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Vigil Neuroscience Trading Down 5.0 %

Shares of VIGL stock opened at $3.26 on Monday. The firm has a 50-day moving average price of $3.68 and a 200 day moving average price of $3.52. Vigil Neuroscience, Inc. has a twelve month low of $2.47 and a twelve month high of $9.24. The company has a market capitalization of $122.52 million, a price-to-earnings ratio of -1.54 and a beta of 1.96.

Vigil Neuroscience (NASDAQ:VIGL) last announced its earnings results on Tuesday, August 13th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.02. As a group, research analysts predict that Vigil Neuroscience, Inc. will post -2.15 earnings per share for the current year.

Analyst Ratings Changes

VIGL has been the subject of several research reports. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price target on shares of Vigil Neuroscience in a research note on Wednesday, August 14th. Wedbush reissued an “outperform” rating and issued a $23.00 target price on shares of Vigil Neuroscience in a research note on Thursday, July 11th. Finally, Guggenheim cut their target price on shares of Vigil Neuroscience from $17.00 to $16.00 and set a “buy” rating for the company in a research note on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to MarketBeat, Vigil Neuroscience presently has a consensus rating of “Moderate Buy” and an average price target of $16.60.

Vigil Neuroscience Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.